Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
Stomach Neoplasm
About this trial
This is an interventional diagnostic trial for Stomach Neoplasm
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with gastric adenocarcinoma pathologically before surgery Patients aged between 20 to 80 Patients with an ECOG 0 or 1 Patients who were confirmed the presence of aberrant left hepatic artery before or during surgery Exclusion Criteria: Patients with abnormal liver function test befor surgery Patients who diagnosed liver cirrhosis or infectious liver disease Patients who underwent liver resection, or chemotherapy for gastric cancer Patients planned for combined liver resection or cholecystectomy during gastrectomy
Sites / Locations
- GangnamSeverance Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group1
Group2
Group3
Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery